,gpt4_turbo_prompt,text,any_cancer_logit,response_logit,progression_or_mixed_logit,brain_met_logit,bone_met_logit,adrenal_met_logit,liver_met_logit,lung_met_logit,node_met_logit,peritoneum_met_logit
0,"A patient with a history of lung cancer has a CT chest showing no evidence of disease. Generate a detailed synthetic imaging report for that study, including a narrative section describing findings in each imaged organ, and an impression section summarizing the findings.","technique: multi-detector computed tomography of the chest was performed without the administration of intravenous contrast. images were acquired from the lung apices to the adrenal glands at end-inspiration in the axial plane with coronal and sagittal reformations.  findings:  lungs and pleura: the lung parenchyma is clear without evidence of nodules, masses, or consolidations. no ground-glass opacities are identified. the major fissures are intact and well-defined. no pleural effusions or significant pleural thickening is noted.  mediastinum and hila: the mediastinal contours are within normal limits. no pathologically enlarged lymph nodes are identified in the mediastinum or hila. the trachea and main bronchi are patent without evidence of intrinsic or extrinsic compression.  heart and great vessels: the heart size is within normal limits for the patient's body habitus. the aorta and its major branches demonstrate normal caliber and course without evidence of aneurysm or dissection. the pulmonary arteries are unremarkable with no signs of pulmonary embolism.  upper abdomen: the visualized portions of the upper abdomen, including the liver, adrenal glands, and upper kidneys, appear unremarkable. no abdominal lymphadenopathy or ascites is present.  bones: the visualized portions of the thoracic cage, spine, and shoulders show no acute osseous abnormalities. there are no lytic or blastic lesions suggestive of metastatic disease.  soft tissues: the chest wall and soft tissues are unremarkable with no masses or edema.  impression: 1. no evidence of recurrent or residual lung cancer is identified on the current non-contrast ct chest examination. 2. no new pulmonary or mediastinal pathology is evident. 3. the heart and great vessels appear normal. 4. no abnormalities are noted in the visualized portions of the upper abdomen. 5. no osseous lesions suggestive of metastatic disease.",-5.851597,-7.968936,-6.969296,-8.094568,-7.708575,-8.880855,-8.243423,-7.1531987,-8.074566,-8.42244
1,"A patient with metastatic breast cancer has a PET-CT showing progressive disease, with metastases in bone and liver.  Generate a detailed synthetic imaging report for that study, including a narrative section describing findings in each imaged organ, and an impression section summarizing the findings.","procedure: positron emission tomography - computed tomography (pet-ct)  clinical history: patient with a known history of breast cancer, currently under treatment. the study is performed to evaluate the response to therapy.  technique: the patient was administered f-18 fluorodeoxyglucose (fdg) intravenously. imaging commenced approximately 60 minutes post-injection. pet-ct images were acquired from the base of the skull to the mid-thighs. ct images were obtained for attenuation correction and anatomic localization purposes.  findings: head and neck: - no hypermetabolic lesions are identified within the visualized portions of the brain. - the structures of the neck, including the thyroid and salivary glands, show no abnormal fdg uptake.  chest: - the primary breast lesion demonstrates increased fdg uptake, consistent with known malignancy. - multiple hypermetabolic foci are seen within the mediastinum, suggestive of nodal metastatic disease. - the lungs are clear of any focal hypermetabolic activity, with no evidence of pulmonary metastases.  abdomen and pelvis: - the liver demonstrates multiple foci of abnormally increased fdg uptake, consistent with hepatic metastases. the largest lesion measures 4.0 cm, located in the right hepatic lobe. - no abnormal fdg uptake is noted in the adrenal glands, kidneys, or other abdominal viscera. - there is no evidence of fdg-avid pelvic lymphadenopathy or pelvic organ involvement.  musculoskeletal: - skeletal survey reveals multiple areas of increased tracer uptake involving the axial and appendicular skeleton, most notably in the vertebral bodies, pelvis, and proximal femurs, indicative of osseous metastatic disease.  impression: 1. progressive metastatic disease is evident, with increased size and number of hepatic lesions compared to the previous study dated [previous study date]. 2. new and progressive osseous metastases are identified, with increased fdg uptake in the axial and appendicular skeleton. 3. no new pulmonary or nodal metastases within the chest are noted since the prior study. 4. continued hypermetabolic activity in the primary breast lesion, without significant change. 5. overall findings are consistent with progressive metastatic breast cancer.",7.564086,-6.0270915,4.2888274,-4.6733117,4.263361,-4.3825836,3.9895804,-3.3880734,-0.032605145,-4.24882
2,"A patient with a history of resected colorectal cancer has a CT abdomen/pelvis performed, showing recurrence in locoregional lymph nodes. Generate a detailed synthetic imaging report for that study, including a narrative section describing findings in each imaged organ, and an impression section summarizing the findings.","technique: multi-detector ct of the abdomen and pelvis was performed with intravenous contrast. oral contrast was administered prior to the examination. axial images were obtained, with coronal and sagittal reformatted images reviewed.  findings:  liver:   the liver parenchyma demonstrates homogeneous enhancement without focal lesions. no intrahepatic biliary ductal dilatation is seen.  gallbladder and biliary tract:   the gallbladder is unremarkable with no evidence of cholelithiasis or wall thickening. the common bile duct is within normal caliber.  pancreas:   the pancreas is normal in size, shape, and enhancement pattern. no pancreatic mass or ductal dilatation is identified.  spleen:   the spleen is normal in size and homogeneous in attenuation. no splenic lesions or infarcts are noted.  adrenal glands:   both adrenal glands are normal in size and morphology.  kidneys and ureters:   the kidneys enhance symmetrically with no evidence of hydronephrosis or stones. the ureters are not dilated.  bladder:   the urinary bladder is well-distended and shows no filling defects or wall thickening.  gastrointestinal tract:   the stomach and small bowel loops are unremarkable. the colon, at the site of prior resection, shows no evidence of primary tumor recurrence. no bowel obstruction or significant wall thickening is noted.  lymph nodes:   there are enlarged lymph nodes in the mesenteric and pericolic regions, the largest measuring approximately 2.5 cm in short-axis diameter. these nodes are suspicious for metastatic involvement.  peritoneum and omentum:   no ascites or peritoneal nodularity is seen. the omentum is unremarkable.  vasculature:   the abdominal aorta and its major branches are patent. no aneurysmal dilatation or significant atherosclerotic disease is present.  bones:   visualized osseous structures show no evidence of lytic or blastic lesions.  impression: 1. no evidence of hepatic, pancreatic, splenic, renal, or adrenal metastasis. 2. enlarged mesenteric and pericolic lymph nodes, the largest measuring approximately 2.5 cm, suggestive of locoregional lymph node recurrence of previously resected colorectal cancer. 3. no evidence of primary tumor recurrence at the site of prior colonic resection. 4. no evidence of peritoneal carcinomatosis or distant metastatic disease.",3.3932426,-4.7544394,-0.45288378,-7.4096627,-7.077359,-3.7449071,-4.5473185,-4.843845,2.6337783,-3.0481186
3,"A patient with metastatic bladder cancer to lymph nodes, bone, and lung undergoes a CT abdomen/pelvis demonstrating response to therapy. Generate a detailed synthetic imaging report for that study, including a narrative section describing findings in each imaged organ, and an impression section summarizing the findings.","ct abdomen/pelvis post-contrast  clinical history:  patient with known metastatic bladder cancer to lymph nodes, bone, and lung currently undergoing treatment.  technique: multiphase ct imaging of the abdomen and pelvis was performed following the administration of intravenous contrast material. oral contrast was administered prior to the study to opacify the gastrointestinal tract.  comparison: ct abdomen/pelvis dated [previous scan date].  findings:  liver: no evidence of hepatic metastasis. the liver parenchyma demonstrates homogeneous enhancement without focal lesions. no biliary ductal dilatation.  gallbladder and biliary tract: gallbladder is normal in size and contour. no gallstones or biliary ductal dilatation.  pancreas: pancreas is normal in size and morphology. no evidence of mass or pancreatic duct dilatation.  spleen: spleen size and attenuation are within normal limits. no splenic lesions.  adrenal glands: adrenal glands are normal in size and shape without evidence of masses.  kidneys and ureters: kidneys demonstrate normal size, shape, and excretory function. no hydronephrosis or stones. ureters are not dilated.  bladder: the bladder wall is thickened, consistent with known primary malignancy. however, there is a decrease in the degree of wall thickening and enhancement compared to the prior study, suggesting a response to therapy. no new mural nodules or intraluminal masses.  lymph nodes: previously noted enlarged para-aortic and pelvic lymph nodes have decreased in size, indicating a positive response to treatment.  bones: known bony metastases in the pelvis and lumbar spine show reduced sclerotic activity and size, consistent with treatment response. no new bony lesions.  lung: although not fully imaged, the lung bases included in the scan demonstrate a decrease in the size of previously noted pulmonary nodules, suggesting a response to therapy.  bowel and mesentery: no evidence of bowel obstruction or focal bowel wall thickening. mesentery is clear with no evidence of mass or lymphadenopathy.  vessels: abdominal aorta and its major branches are patent. no evidence of aneurysm or dissection.  impression: 1. decreased size of bladder wall thickening, consistent with a response to ongoing therapy for known bladder cancer. 2. reduction in size of previously enlarged para-aortic and pelvic lymph nodes, suggestive of a positive therapeutic response. 3. improvement in known bony metastases with decreased sclerotic activity, indicating a response to treatment. 4. decreased size of previously noted pulmonary nodules at the lung bases, consistent with a response to therapy. 5. no new metastatic disease identified in the abdomen or pelvis.",5.523456,3.159149,-3.5552478,-4.472274,2.8318183,-4.006611,-4.5604925,1.8046097,1.7456318,-5.086144
4,"A patient with metastatic bladder cancer to lymph nodes, bone, and lung undergoes a CT abdomen/pelvis demonstrating response to therapy. Generate a detailed synthetic imaging report for that study, including a narrative section describing findings in each imaged organ, and an impression section summarizing the findings.","procedure: mri brain with and without iv contrast  clinical history: clear cell renal cell carcinoma with known brain metastases, status post whole brain radiation therapy. evaluation for disease progression.  technique: multiplanar, multisequence mri of the brain was performed with and without the administration of gadolinium-based contrast agent.  comparative data: prior mri dated [redacted]  findings:  brain parenchyma: - multiple enhancing lesions are identified throughout the cerebral hemispheres, with the largest lesion measuring approximately 1.5 cm in the right frontal lobe. this lesion demonstrates surrounding vasogenic edema and mass effect with local sulcal effacement. - interval increase in the number and size of enhancing lesions compared to the prior study, consistent with disease progression. - evidence of post-radiation changes, including diffuse cerebral atrophy and focal areas of t2/flair hyperintensity within the white matter, likely representing radiation leukoencephalopathy. - no evidence of acute infarct or intracranial hemorrhage.  ventricular system and cisterns: - mild ventriculomegaly, likely secondary to mass effect and cerebral atrophy. basal cisterns are patent.  skull base and calvarium: - no evidence of abnormal enhancement or destructive lesions involving the skull base or calvarium.  orbits: - orbits are unremarkable with no evidence of intraorbital metastatic disease.  paranasal sinuses and mastoid air cells: - paranasal sinuses and mastoid air cells are clear.  contrast enhancement: - the enhancing lesions demonstrate heterogeneous contrast uptake, which is characteristic of metastatic disease. no new areas of abnormal leptomeningeal enhancement are identified.  impression: 1. progression of metastatic disease within the brain, as evidenced by an increased number and size of enhancing lesions compared to the prior study. 2. post-radiation changes are present, including cerebral atrophy and white matter hyperintensities, without evidence of acute radiation necrosis. 3. no new hemorrhage or acute infarct identified. 4. continued surveillance with mri is recommended to monitor disease progression and response to any subsequent therapies.",5.2515187,-5.4113398,3.9012554,3.6707604,-5.199081,-6.6414304,-5.5897455,-5.96336,-6.435937,-7.572319
